Gerold Meinhardt

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Riccardo Lencioni, Angelo Luca, J. Bruix, 2016, Journal of hepatology.

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Masatoshi Kudo, Osamu Yokosuka, Gianluca Masi, 2017, The Lancet.